Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI) require antithrombotic therapy to prevent thrombotic events.
• Traditional triple antithrombotic therapy (aspirin, P2Y12 inhibitor, oral anticoagulant) is associated with high bleeding rates.

Purpose of the Study:

• To review contemporary antithrombotic management strategies for AF patients undergoing PCI.
• To evaluate the balance between ischemic and bleeding risks in this patient population.

Main Methods:

• Analysis of recent clinical trials evaluating dual antithrombotic therapy in AF patients undergoing PCI.
• Comparison of dual versus triple antithrombotic therapy regimens.

Main Results:

• Dual antithrombotic therapy significantly reduces bleeding events compared to triple therapy.
• Dual therapy demonstrates no increase in ischemic events.
• Clopidogrel is the preferred P2Y12 inhibitor in dual regimens.
• Novel oral anticoagulants (NOACs) like rivaroxaban and dabigatran are preferred oral anticoagulants.

Conclusions:

• Dual antithrombotic therapy represents a safer and effective alternative to triple therapy for AF patients undergoing PCI.
• Current evidence supports the use of specific NOACs and P2Y12 inhibitors in dual regimens.